Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab deruxtecan + rilvegostomig
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Trastuzumab deruxtecan + rilvegostomig** is a combination investigational therapy used in clinical trials for several advanced HER2-expressing cancers. Trastuzumab deruxtecan (T-DXd, DS-8201a) is an antibody-drug conjugate targeting HER2: its monoclonal antibody (trastuzumab) binds HER2 receptor and delivers a cytotoxic payload (deruxtecan) directly to cancer cells. Rilvegostomig (AZD2936) is a bispecific monoclonal antibody targeting both programmed cell death protein 1 (PD-1) and TIGIT, enhancing immune response by blocking these checkpoints to promote T-cell mediated tumor destruction. The combination aims to produce synergistic antitumor effects, combining direct cytotoxicity and immune checkpoint inhibition. Main indications under investigation include HER2-expressing endometrial cancer, gastric cancer, and biliary tract cancer[3][6][7][4].
- Brand names
- Enhertu
- Other names
- trastuzumab deruxtecanT-DXdDS-8201aDS8201aDS 8201arilvegostomigAZD2936AZD-2936AZD 2936trastuzumab deruxtecan + rilvegostomig
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TIGIT (T cell immunoreceptor with Ig and ITIM domains)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab deruxtecan + rilvegostomig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab deruxtecan + rilvegostomig.